研究单位：[1]Betta Pharmaceuticals Co., Ltd.[2]Zhejiang Cancer Hospital[3]Fujian Hospital for Chest Tumors & Tuberculosis Diseases,Fuzhou,Fujian,China,350000[4]Fujian Provincal Hospital,Fuzhou,Fujian,China,350001[5]Fujian Provincal Cancer Hospital,Fuzhou,Fujian,China,350014[6]The second hospital of Xiamen City,Xiamen,Fujian,China,361024[7]Hunan Provincal Cancer Hospital,Changsha,Hunan,China,410006[8]The Second People's Hospital of Sichuan,Chengdu,Sichuan,China,610041[9]Sir Run Run Shaw Hospital,Hangzhou,Zhejiang,China,310000[10]The First Affiliated Hospital of Medical School of Zhejiang University,Hangzhou,Zhejiang,China,310000[11]The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310000[12]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310000[13]Zhejiang Traditional Chinese Medical Hospital,Hangzhou,Zhejiang,China,310006[14]Zhejiang Hospital,Hangzhou,Zhejiang,China,310007[15]Zhejiang Provincial People''s Hospital,Hangzhou,Zhejiang,China,310014[16]Yinzhou People''s Hospital,Ningbo,Zhejiang,China,315040[17]Ningbo Medical Treatment Center Lihuili Hospital,Ningbo,Zhejiang,China,315046[18]Taizhou Hospital of Zhejiang Province,Taizhou,Zhejiang,China,317000[19]The First Affiliated Hospital of Wenzhou Medical College,Wenzhou,Zhejiang,China,325000
研究目的：
The primary purposes of this study are to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer that achieve stable disease after 8 weeks routine therapy.
